Results from the phase 3 VERIFY trial showed that rusfertide significantly improved hematocrit control, reduced therapeutic phlebotomy requirements, and improved patient-reported symptom burden in patients with phlebotomy-dependent...
Results from the phase 3 VERIFY trial showed that rusfertide significantly improved hematocrit control, reduced therapeutic phlebotomy requirements, and improved patient-reported symptom burden in patients with phlebotomy-dependent...
Results from the phase 3 evERA Breast Cancer trial demonstrated significantly improved progression-free survival with giredestrant plus everolimus compared with standard endocrine therapy plus everolimus in previously treated patients with...
Results from the phase 3 evERA Breast Cancer trial demonstrated significantly improved progression-free survival with giredestrant plus everolimus compared with standard endocrine therapy plus everolimus in previously treated patients with...
Results from the phase 3 GIMEMA ALL2820 trial showed that frontline ponatinib plus blinatumomab significantly improved event-free survival and molecular response compared with imatinib plus chemotherapy in adult patients with newly diagnosed...
Results from the phase 3 GIMEMA ALL2820 trial showed that frontline ponatinib plus blinatumomab significantly improved event-free survival and molecular response compared with imatinib plus chemotherapy in adult patients with newly diagnosed...
Results from the phase 3 REGAL trial demonstrated that galinpepimut-S maintenance significantly improved overall survival compared with best available treatment in acute myeloid leukemia following second or later remission, supporting the...
Results from the phase 3 REGAL trial demonstrated that galinpepimut-S maintenance significantly improved overall survival compared with best available treatment in acute myeloid leukemia following second or later remission, supporting the...
Results from a prospective study demonstrated that longitudinal tumor-naïve multimodal circulating cell-free DNA minimal residual disease monitoring stratified recurrence risk following curative-intent resection of non-small cell lung cancer...
Results from a prospective study demonstrated that longitudinal tumor-naïve multimodal circulating cell-free DNA minimal residual disease monitoring stratified recurrence risk following curative-intent resection of non-small cell lung cancer...
Results from a deep learning study demonstrated high accuracy in classifying FGFR3::TACC3 fusion-positive non-small cell lung cancer using hematoxylin and eosin-stained whole-slide images, suggesting that artificial intelligence may identify...
Results from a deep learning study demonstrated high accuracy in classifying FGFR3::TACC3 fusion-positive non-small cell lung cancer using hematoxylin and eosin-stained whole-slide images, suggesting that artificial intelligence may identify...
Results from a health-related quality-of-life analysis of the phase 3 MANEUVER trial demonstrated sustained improvements in patient-reported health status with pimicotinib in patients with tenosynovial giant cell tumor, with benefits...
Results from a health-related quality-of-life analysis of the phase 3 MANEUVER trial demonstrated sustained improvements in patient-reported health status with pimicotinib in patients with tenosynovial giant cell tumor, with benefits...
Updated 2-year results from the phase 3 MANEUVER trial demonstrated sustained improvements in pain, stiffness, range of motion, and physical function with pimicotinib in patients with tenosynovial giant cell tumor, alongside durable tumor...
Updated 2-year results from the phase 3 MANEUVER trial demonstrated sustained improvements in pain, stiffness, range of motion, and physical function with pimicotinib in patients with tenosynovial giant cell tumor, alongside durable tumor...
Results from a clinical validation study demonstrated that cell-free DNA methylation-based fusion epigenotyping detected non-EML4-ALK fusions in non-small cell lung cancer with high sensitivity and specificity, supporting its potential to...
Results from a clinical validation study demonstrated that cell-free DNA methylation-based fusion epigenotyping detected non-EML4-ALK fusions in non-small cell lung cancer with high sensitivity and specificity, supporting its potential to...
Updated results from the phase 2 FIREFLY-1 trial demonstrated prolonged treatment-free intervals with tovorafenib in relapsed or refractory BRAF-altered pediatric low-grade glioma, with most patients entering observation remaining off therapy...
Updated results from the phase 2 FIREFLY-1 trial demonstrated prolonged treatment-free intervals with tovorafenib in relapsed or refractory BRAF-altered pediatric low-grade glioma, with most patients entering observation remaining off therapy...